Leone Chare1, John R Hodges2, Cristian E Leyton3, Ciara McGinley4, Rachel H Tan5, Jillian J Kril6, Glenda M Halliday1. 1. Neuroscience Research Australia, Sydney, Australia UNSW Medicine, University of New South Wales, Sydney, Australia. 2. Neuroscience Research Australia, Sydney, Australia UNSW Medicine, University of New South Wales, Sydney, Australia ARC Centre of Excellence in Cognition and its Disorders, Sydney, Australia. 3. Neuroscience Research Australia, Sydney, Australia ARC Centre of Excellence in Cognition and its Disorders, Sydney, Australia. 4. Disciplines of Pathology, Sydney Medical School, The University of Sydney, Sydney, Australia. 5. Neuroscience Research Australia, Sydney, Australia. 6. Disciplines of Pathology, Sydney Medical School, The University of Sydney, Sydney, Australia Disciplines of Medicine, Sydney Medical School, The University of Sydney, Sydney, Australia.
Abstract
OBJECTIVE: To assess the impact of new clinical diagnostic criteria for frontotemporal dementia (FTD) syndromes, including primary progressive aphasias (PPA), on prior clinical diagnosis and to explore clinicopathological correlations. METHODS: 178 consecutive neuropathologically ascertained cases initially diagnosed with a FTD syndrome were collected through specialist programmes: the Cambridge Brain Bank, UK, and Sydney Brain Bank, Australia. 135 cases were reclassified using the revised diagnostic criteria into behavioural variant (bvFTD), semantic variant PPA (sv-PPA), non-fluent/agrammatic variant PPA (nfv-PPA) and logopenic variant PPA (lv-PPA). Pathological diagnoses included FTLD-tau, FTLD-TDP, FTLD-FUS, FTLD-UPS, FLTD-ni and Alzheimer's disease (AD). Statistical analyses included χ(2) tests, analyses of variance and discriminant statistics. RESULTS: Comparison of the original and revised diagnosis revealed no change in 90% of bvFTD and sv-PPA cases. By contrast, 51% of nfv-PPA cases were reclassified as lv-PPA, with apraxia of speech and sentence repetition assisting in differentiation. Previous patterns of pathology were confirmed, although more AD cases occurred in FTD syndromes (10% bvFTD, ∼15% sv-PPA and ∼30% nfv-PPA) than expected. AD was the dominant pathology (77%) of lv-PPA. Discriminant analyses revealed that object agnosia, phonological errors and neuropsychiatric features differentiated AD from FTLD. CONCLUSIONS: This study provides pathological validation that the new criteria assist with separating PPA cases with AD pathology into the new lv-PPA syndrome and found that a number of diagnostic clinical features (disinhibition, food preferences and naming) did not assist in discriminating the different FTD syndromes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: To assess the impact of new clinical diagnostic criteria for frontotemporal dementia (FTD) syndromes, including primary progressive aphasias (PPA), on prior clinical diagnosis and to explore clinicopathological correlations. METHODS: 178 consecutive neuropathologically ascertained cases initially diagnosed with a FTD syndrome were collected through specialist programmes: the Cambridge Brain Bank, UK, and Sydney Brain Bank, Australia. 135 cases were reclassified using the revised diagnostic criteria into behavioural variant (bvFTD), semantic variant PPA (sv-PPA), non-fluent/agrammatic variant PPA (nfv-PPA) and logopenic variant PPA (lv-PPA). Pathological diagnoses included FTLD-tau, FTLD-TDP, FTLD-FUS, FTLD-UPS, FLTD-ni and Alzheimer's disease (AD). Statistical analyses included χ(2) tests, analyses of variance and discriminant statistics. RESULTS: Comparison of the original and revised diagnosis revealed no change in 90% of bvFTD and sv-PPA cases. By contrast, 51% of nfv-PPA cases were reclassified as lv-PPA, with apraxia of speech and sentence repetition assisting in differentiation. Previous patterns of pathology were confirmed, although more AD cases occurred in FTD syndromes (10% bvFTD, ∼15% sv-PPA and ∼30% nfv-PPA) than expected. AD was the dominant pathology (77%) of lv-PPA. Discriminant analyses revealed that object agnosia, phonological errors and neuropsychiatric features differentiated AD from FTLD. CONCLUSIONS: This study provides pathological validation that the new criteria assist with separating PPA cases with AD pathology into the new lv-PPA syndrome and found that a number of diagnostic clinical features (disinhibition, food preferences and naming) did not assist in discriminating the different FTD syndromes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Miguel A Santos-Santos; Gil D Rabinovici; Leonardo Iaccarino; Nagehan Ayakta; Gautam Tammewar; Iryna Lobach; Maya L Henry; Isabel Hubbard; Maria Luisa Mandelli; Edoardo Spinelli; Zachary A Miller; Peter S Pressman; James P O'Neil; Pia Ghosh; Andreas Lazaris; Marita Meyer; Christa Watson; Soo Jin Yoon; Howard J Rosen; Lea Grinberg; William W Seeley; Bruce L Miller; William J Jagust; Maria Luisa Gorno-Tempini Journal: JAMA Neurol Date: 2018-03-01 Impact factor: 18.302
Authors: Edoardo G Spinelli; Maria Luisa Mandelli; Zachary A Miller; Miguel A Santos-Santos; Stephen M Wilson; Federica Agosta; Lea T Grinberg; Eric J Huang; John Q Trojanowski; Marita Meyer; Maya L Henry; Giancarlo Comi; Gil Rabinovici; Howard J Rosen; Massimo Filippi; Bruce L Miller; William W Seeley; Maria Luisa Gorno-Tempini Journal: Ann Neurol Date: 2017-03-20 Impact factor: 10.422
Authors: Hugo Botha; Joseph R Duffy; Jennifer L Whitwell; Edythe A Strand; Mary M Machulda; Christopher G Schwarz; Robert I Reid; Anthony J Spychalla; Matthew L Senjem; David T Jones; Val Lowe; Clifford R Jack; Keith A Josephs Journal: Cortex Date: 2015-05-27 Impact factor: 4.027
Authors: C Liguori; A Romigi; N B Mercuri; M Nuccetelli; F Izzi; M Albanese; G Sancesario; A Martorana; G M Sancesario; S Bernardini; M G Marciani; F Placidi Journal: J Neurol Date: 2014-08-14 Impact factor: 4.849
Authors: Jennifer L Whitwell; Kejal Kantarci; Stephen D Weigand; Emily S Lundt; Jeffrey L Gunter; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Anthony J Spychalla; Daniel A Drubach; Ronald C Petersen; Val J Lowe; Clifford R Jack; Keith A Josephs Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472